Novo Nordisk (NVO) fell nearly 10% in U.S. premarket trading on Monday after the Danish drugmaker said a pill version of Ozempic (semaglutide) did not slow the progression of Alzheimer’s disease in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback